Kobayashi Pharmaceutical reports mixed Q3 results: sales down, net profit up

Kobayashi Pharmaceutical reported consolidated financial results for the third quarter ended September 30, 2025, with net sales reaching JPY 112,038 million, a 2.1% decrease year-over-year. Operating profit, however, experienced a notable decline of 32.3% to JPY 11,495 million, while ordinary profit also fell by 27.9% to JPY 12,930 million.

In contrast to the revenue and operating profit downturns, net profit attributable to parent company shareholders saw a substantial increase of 27.4% to JPY 6,809 million, resulting in basic earnings per share of JPY 91.60. Total assets decreased by JPY 3,915 million from the previous fiscal year-end to JPY 261,453 million, primarily due to reductions in cash and deposits, and notes and accounts receivable.

The company maintains its full-year consolidated earnings forecast for the fiscal year ending December 2025, projecting net sales of JPY 171,000 million, operating profit of JPY 14,000 million, and net profit attributable to parent company shareholders of JPY 10,500 million.